Translational Biomarkers: Pathways to Phase II Survival
| Type | Conference |
|---|---|
| Date |
October 5, 2008
to October 7, 2008 |
| Venue |
The Crown Plaza Center City Philadelphia, PA US |
| Chemistry Specialties |
|
| Chemistry Techniques |
|
| Contact |
ACS Office of Continuing Education ACS 1155 Sixteenth Street, NW Washington, DC, 20036 US (202) 872-4508 (202) 872-6336 service@acs.org |
| Add event to calendar |
|
The first ACS ProSpectives conference on translational Biomarkers will be chaired by Dr. Lisa Gold, Executive Director of Merck, and Dr. Paul Galatsis, Associate Research Fellow of Pfizer. Together they have gathered a group of highly regarded pharmaceutical industry and academic scientists who will lecture and present case studies over the course of the two day program. The high attrition rates experienced in Phase II has multiple implications for drug discovery and the pharmaceutical industry in general. This conference is geared specifically for medicinal chemists and focuses on the pathways for developing translational biomarkers. These tools facilitate the translation of preclinical candidates into clinical programs with a greater degree of confidence and have the potential to increase the probability of their success.
